olvimulogene nanivacirepvec

AXP000093.1 · Oncolytic virus

Platform
vaccinia virus (Lister/LIVP, triple-deleted)
Originator
Genelux
Sponsor
Genelux

Names

NameTypeSource
olvimulogene nanivacirepvecpreferred name, INNcurator, ncit
Olvi-Vecbrandncit
GLV-1h68codencit
GL-ONC1former codencit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
Lister (LIVP)
Replication
conditionally replicating
Modifications
F14.5L, J2R (thymidine kinase) and A56R (haemagglutinin) loci disrupted by expression cassettes
Transgenes
RUC-GFP, LacZ, gusA
Route
intravenous, intraperitoneal, intrapleural, intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C79833
Wikidata
Q140775697
FDA UNII
CF19SF72O5

Approvals

No regulatory approval recorded.

Clinical trials (10)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06463665Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingPhase 22024-09-262027-02142Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Recurrent; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV
NCT07136285Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLCRecruitingPhase 1/22023-07-242026-1227SCLC, Extensive Stage
NCT05281471Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)RecruitingPhase 32022-08-312026-12186Endometrioid Ovarian Cancer; Fallopian Tube Cancer; High-grade Serous Ovarian Cancer; Ovarian Clear Cell Carcinoma; Platinum-refractory Ovarian Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Cancer
NCT02759588Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerCompletedPhase 1/22016-052021-12-3146Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Carcinomatosis
NCT02714374GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ CancersTerminatedPhase 12016-03-252019-08-065Solid Organ Cancers
NCT01766739Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and MesotheliomaCompletedPhase 12013-012024-10-2418Lung Cancer
NCT01584284Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck CancerCompletedPhase 12012-042015-0619Cancer of Head and Neck
NCT01443260A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal CarcinomatosisCompletedPhase 1/22012-022014-099Peritoneal Carcinomatosis
NCT00794131Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid TumorsCompletedPhase 12008-112015-1143Advanced Cancers (Solid Tumors)
NCT03420430Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of CareNo longer availableAcute Myeloid Leukemia (6 Patients); Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42383154Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.Gynecologic oncology reports2026cited by trial NCT02759588
PMID 42780413Deep and durable response to re-challenge with platinum-based therapy in a platinum-relapsed small cell lung cancer patient following Olvi-Vec oncolytic immunotherapy: a case report.Frontiers in oncology2026name in title: Olvi-Vec
PMID 36875061Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.Frontiers in immunology2023cited by trial NCT01766739
PMID 37227734Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.JAMA oncology2023cited by trial NCT02759588
PMID 37666539A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2023cited by trial NCT05281471
PMID 34686353A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.Gynecologic oncology2021cited by trial NCT05281471
PMID 31567308Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient.Anti-cancer drugs2019name in title: GL-ONC1
PMID 29773661Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.Clinical cancer research : an official journal of the American Association for Cancer Research2018cited by trial NCT01443260
PMID 28679776Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research2017name in title: GL-ONC1

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42636898Killing to cure: harnessing poxvirus-driven cell death for viral immunotherapy.Immunology letters2026name in abstract: olvimulogene nanivacirepvec
PMID 32631270Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.BMC cancer2020name in title: GLV-1h68
PMID 30885937PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in abstract: GLV-1h68
PMID 31142183Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models.Bioengineered2019name in abstract: GLV-1h68
PMID 28607950Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.Molecular therapy oncolytics2017name in title: GLV-1h68
PMID 25244076Silk-elastin-like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus.Head & neck2016name in abstract: GLV-1h68
PMID 27116656Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma.International journal of cancer2016name in abstract: GLV-1h68
PMID 27783991Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis.Oncotarget2016name in abstract: GLV-1h68
PMID 24978211Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.International journal of cancer2015name in abstract: GLV-1h68
PMID 26072410Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring.Methods in molecular biology (Clifton, N.J.)2015name in title: GLV-1h68
PMID 26348361Drug-Encoded Biomarkers for Monitoring Biological Therapies.PloS one2015name in abstract: GLV-1h68
PMID 26584530Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma.Cancer gene therapy2015name in title: GLV-1h68
PMID 23624923Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.Oncogene2014name in abstract: GLV-1h68
PMID 24957667Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.Surgery2014name in title: GLV-1h68
PMID 25030093Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice.Journal of translational medicine2014name in abstract: GLV-1h68
PMID 25482233Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.Bioengineered2014name in abstract: GLV-1h68
PMID 23429949Oncolytic vaccinia virus therapy of salivary gland carcinoma.JAMA otolaryngology-- head & neck surgery2013name in abstract: GLV-1h68
PMID 23441176Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI).PloS one2013name in abstract: GLV-1h68
PMID 23531320Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.Journal of translational medicine2013name in title: GLV-1h68
PMID 23729266Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.International journal of cancer2013name in abstract: GLV-1h68
PMID 23765443Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.Molecular therapy : the journal of the American Society of Gene Therapy2013name in abstract: GLV-1h68
PMID 22341347Effective oncolytic vaccinia therapy for human sarcomas.The Journal of surgical research2012name in abstract: GLV-1h68
PMID 22379115Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.Clinical cancer research : an official journal of the American Association for Cancer Research2012name in abstract: GLV-1h68
PMID 22615950Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.PloS one2012name in abstract: GLV-1h68
PMID 22901246Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells.Journal of translational medicine2012name in title: GLV-1h68
PMID 22912675Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter.PloS one2012name in abstract: GLV-1h68
PMID 22917220Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors.BMC cancer2012name in abstract: GLV-1h68
PMID 23049897Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.PloS one2012name in title: GLV-1h68
PMID 23131031Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Human gene therapy methods2012name in abstract: GLV-1h68
PMID 20829890Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.Cancer gene therapy2011name in title: GLV-1h68
PMID 21249314Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts.International journal of oncology2011name in abstract: GLV-1h68
PMID 21453532Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus.Journal of translational medicine2011name in abstract: GLV-1h68
PMID 21779374Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.PloS one2011name in title: GLV-1h68
PMID 21951588Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.Journal of translational medicine2011name in abstract: GLV-1h68
PMID 22011439Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68.BMC cancer2011name in title: GLV-1h68
PMID 20379368Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.Journal of biomedicine & biotechnology2010name in title: GLV-1h68
PMID 20631910Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.Journal of oncology2010name in title: GLV-1h68
PMID 18949014Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.Cancer gene therapy2009name in abstract: GLV-1h68
PMID 19035444Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model.International journal of cancer2009name in title: GLV-1h68
PMID 19139123Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.Molecular cancer therapeutics2009name in title: GLV-1h68
PMID 19287510A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging.Molecular medicine (Cambridge, Mass.)2009name in abstract: GLV-1h68
PMID 19580655Oncolytic vaccinia therapy of squamous cell carcinoma.Molecular cancer2009name in abstract: GLV-1h68
PMID 19583830Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.BMC genomics2009name in title: GLV-1h68
PMID 19617539Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.Proceedings of the National Academy of Sciences of the United States of America2009name in abstract: GLV-1h68
PMID 19701652The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation.Molecular genetics and genomics : MGG2009name in title: GLV-1h68
PMID 18697871Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.The Journal of clinical endocrinology and metabolism2008name in abstract: GLV-1h68
PMID 18754710Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.Human gene therapy2008name in title: GLV-1h68
PMID 17942938Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.Cancer research2007name in abstract: GLV-1h68
PMID 18063085Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus.Surgery2007name in abstract: GLV-1h68

Notes

GLV-1h68/GL-ONC1, renamed Olvi-Vec and given the INN olvimulogene nanivacirepvec. Dosed intravenously, intraperitoneally and intrapleurally; phase 3 OnPrime (GOG-3076) in platinum-resistant ovarian cancer ongoing.

How to cite

olvimulogene nanivacirepvec (AXP000093.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000093.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.